Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Table 3 Clinicopathological Characteristics of all metastatic patients in this study

Characteristic	Patients (n = 96)	Percent
Age, years (mean ± SD)	51 ± 7.5
Menopausal status
pre-	44	45.8
post-	52	54.2
Tumor size
≤ 20 mm	17	17.7
> 20 mm	77	80.2
unknown	2	2.1
LN status
positive	63	65.6
negative	33	34.4
Histological type
ductal	83	86.5
special^a	13	13.5
LVI status
positive	63	65.6
negative	25	26.1
unknown	8	8.3
Operation status
partial mastectomy	17	17.8
mastectomy	79	82.2
Stage at the primary diagnosis
1	11	11.5
2	48	50
3	34	35.4
4	1	1.0
unknown	2	2.0
Chemotherapy
adjuvant	83	86.5
none	13	13.5
Hormone therapy
adjuvant	50	52.1
none	46	47.9
Site of recurrence
brain	26	27.0
lung	8	8.3
liver	1	1.0
ovary	2	2.1
chest wall	13	13.5
lymph node	15	15.6
distant skin	7	7.3
bone	24	25

Abbreviations: LN lymph node, LVI lymphovascular invasion, SD standard deviation
^aSpecial type is invasive breast carcinoma except invasive ductal carcinoma

ISSN: 1471-2407